Peginterferon alfa-2a and ribavirin combination therapy in patients with HBeAg [hepatitis B envelope antigen]-negative chronic HBV [hepatitis B virus] infection (PARC Study).
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PARC
- 11 May 2010 Results were published in the American Journal of Gastroenterology.
- 15 Feb 2008 Status changed from recruiting to completed; according to Roche.
- 16 Nov 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History